CD274 and neoplasm: However, it is necessary to consider that these results may have been affected by the tumour expression of PD-L1 being lower than 25%.PFS and OS rates were shown to be similar in both studies without any significant differences [65,68], which emphasizes the idea that durvalumab is a mAb capable of improving the survival of these patients regardless of the expression of PD-L1.